Incyte (FRA:ICY) Ending Cash Position : €2,948 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Incyte Ending Cash Position?

Incyte's Ending Cash Position for the quarter that ended in Dec. 2023 was €2,948 Mil.

Incyte's quarterly Ending Cash Position increased from Jun. 2023 (€2,892 Mil) to Sep. 2023 (€3,026 Mil) but then declined from Sep. 2023 (€3,026 Mil) to Dec. 2023 (€2,948 Mil).

Incyte's annual Ending Cash Position increased from Dec. 2021 (€1,822 Mil) to Dec. 2022 (€2,788 Mil) and increased from Dec. 2022 (€2,788 Mil) to Dec. 2023 (€2,948 Mil).

Incyte Ending Cash Position Historical Data

The historical data trend for Incyte's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Ending Cash Position Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

1,650.34

1,245.14

1,822.36

2,787.75

2,948.36

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															2,787.75	2,636.47	2,891.61	3,025.52	2,948.36

Incyte Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Incyte's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2708.011	+	240.347
	=	2,948

Incyte's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2960.945	+	-12.587
	=	2,948

Incyte Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Incyte's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (FRA:ICY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (FRA:ICY) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (FRA:ICY) Headlines

No Headlines